Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00952692Phase 1Completed

Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer

Role: lead

NCT02687009Phase 1Terminated

A Study of Niclosamide in Patients With Resectable Colon Cancer

Role: lead

NCT00103142Phase 2Completed

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Role: lead

NCT00027534Phase 1Completed

Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer

Role: lead

NCT00672152Phase 1Terminated

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

Role: lead

NCT00437502Phase 1Completed

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Role: lead

All 6 trials loaded